Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.65 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IL15 | P40933 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
| ▸ | IL15RA | Q13261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248221 | 1.00 | SLC22A12 (0.65) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Potassium SCHEMBL30892115 | 0.99 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL14921536 | 0.99 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL248724 | 0.93 | SLC22A12 (0.62) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Potassium Ion SCHEMBL14921535 | 0.92 | SLC22A12 (0.61) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Potassium Ion SCHEMBL30014976 | 0.92 | SLC22A12 (0.61) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL249359 | 0.91 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL10029197 | 0.91 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1719573 | 0.91 | SLC22A12 (0.65) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL12056187 | 0.90 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| EP-4005560-B1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3730503-B1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX INC (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4065116-B1 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | GILEAD SCIENCES INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12521388-B2 | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4674417-A1 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4658277-A1 | METHODS OF TREATING VIRAL INFECTION | Griffith University (AU) | 2025-12-10 | — | — | EP | disclosed |
| EP-4643882-A2 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250270192-A1 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3982996-A1 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2022-03-24 | — | — | US | disclosed |
| US-20220072021-A1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-11234985-B2 | Antiviral therapy | VIIV HEALTHCARE COMPANY | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | NSUN2, IRF3, DNMT3B | SLC22A12 4354/4885CYP2C9 4630/4885CYP2C19 4657/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | SLC22A12 4678/4885CYP2C9 1867/4885CYP2C19 1772/4885 |
| US-20250270192-A1 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | SERPINB1, TSG101, SAP18 | SLC22A12 1762/4885CYP2C9 4196/4885CYP2C19 4172/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | SLC22A12 4751/4885CYP2C9 2554/4885CYP2C19 1873/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | SLC22A12 3911/4885CYP2C9 2262/4885CYP2C19 2062/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | SLC22A12 1707/4885CYP2C9 3771/4885CYP2C19 2444/4885 |
| US-20220072021-A1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | EIF2AK2, SARS1, ZC3HAV1 | SLC22A12 3244/4885CYP2C9 425/4885CYP2C19 507/4885 |
| US-11234985-B2 | Antiviral therapy | SAMHD1, EIF2AK2, MAVS | SLC22A12 3347/4885CYP2C9 3970/4885CYP2C19 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.